nextpoint therapeutics

Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Postings, Latest The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. To learn more, visit nextpointtx.com. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. Bayer Athletes, Disabled Lists Featuring This Company Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. Sports, Promotion and Follow-up Questions, How to These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). our employees, International Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. Bayers leadership in agriculture provides tailored solutions 5. Position, Position We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Protection, Environmental About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Use, Privacy Water Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. for States, Australia, Canada or Japan. or the solicitation of an offer to buy or subscribe for, any securities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. farmers to plant, grow and protect their harvests using less Governance, Sustainability The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of Get the latest business insights from Dun & Bradstreet. For more information, go to www.bayer.com. Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. Sports, Successful While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. High 61F. on Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. Management, Bayer Procurement Management Trainee Program, Bridging In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. For more information, go to www.bayer.com. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. Portal, Countermotions For more information, go to. Supply Chain Management Trainee Program, International Governance, Board of Our Privacy Notice does not apply to Third-Party Sites. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. securities in any Relevant Member State means the communication in any form and by any means of The Bayer brand stands for trust, reliability and quality throughout the world. You are currently on the Bayer global website. 2021 Feb;9(2):156-169. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. an offer to the public of the securities has not been made and will not be made in such Relevant Janakiram M, Chinai JM, Fineberg S, et al. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. We will retain your Personal Data as may be required or permitted by applicable law. Requests may be made only once a year and are free of charge. The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. Bayer Global Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. Headquarters, Dominican designed to prevent, alleviate and treat diseases. us, Talent Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. of Biodiversity, Modern Vote, Voting Board, Document Download The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. of Learn more about join Statement, Cookie The United States data protection and other laws might not be as comprehensive as those in your country. Global R&D, Events & NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Announcements, Sustainability & & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. we For more information. Effective Date. Bayer. About. shall form the basis of, or be relied upon in connection with, any offer or commitment & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Press release content from Business Wire. YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm Republic, Ireland, Republic Tool, Innovation NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. Global, Bayer This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. +49 2173 380. & Proposals for Election, Stockholder the Bayer press portal. offering or an invitation to the public in connection with any offer within the meaning of Education, Health, Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. Bayer Global Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). 1 Wei Y, Ren X, Galbo PM Jr, et al. on Patients, Beware of Medical Our team of . Leaps by Bayer, Bayer AG's impact investment arm,. INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. 13353 Berlin Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. Access to electronic versions of these materials is being made available on this webpage by Bayer in 2 Bhatt RS, Berjis A, Konge JC, et al. Investing in a stronger future - for our shareholders, and We will respond to reasonable requests as soon as practicable and as required by law. Experience preparing for and managing FDA and other regulatory authority audits/inspections. We do not accept any responsibility or liability for these policies and procedures. Any person KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. prohibited or restricted. Phone: Fighting Counterfeit Drugs, New Safety the world. We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. materials. 24. Investing in a stronger future - for our shareholders, and for the world. Agriculture, Growth Member State, except that an offer to the public in such Relevant Member State of any securities may 2013 Jun 11;110(24):9879-84. person to whom it is unlawful to make such offer or solicitation. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Zealand, Palestinian NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Use the Website for any purpose that is unlawful or prohibited by these Terms. land, water and energy. Looking for a job in an innovative company? She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. The investment portfolio includes more than 50 companies. Degree in nursing, life sciences or a related discipline preferred. Financial Insect Decline, Raising We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Strategy, Bio Revolution NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced Dr. Zang is professor of microbiology & immunology, of medicine, . In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. Stories, Annual the Market, Pharmaceutical Digital in Warsaw, Bayer | Learn more about Anne Koehler, PhD's . Stewardship, Pharmaceuticals Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. Germany The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Governance, Sustainability the Luxembourg Stock Exchange (www.bourse.lu). Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Science, Business We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. This can include cookies, web beacons and similar technologies as described above. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be Management, Code of Conduct Worldwide, News & Consensus, Return Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together We encourage you to review this Privacy Notice often to stay informed of how we may process your information. Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. be made at any time under the following exemptions from the Prospectus Directive, if they have been Drs. Experience with Ph 1-3 immuno-oncology clinical trials preferred. Responsible Care, Bayer The effective date of these Terms is May 18, 2022. . To exercise your rights, you may contact us as at. Trends, Rise Cookies can remember login information, preferences, and similar information. find Bayer country websites and for He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . FAQs, Digital Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. You can use our locations menu to find Bayer country websites and offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in HR Trainee Program, International We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . 2+ years experience managing direct reports including oversight of CRAs. State. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells Protection Products & Seeds, Supplier This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Lanka, Taiwan, As a leader in healthcare, Bayer provides innovative NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized.

Phil Robertson Speaking Schedule 2021, Boy Scouts Lost In Grand Canyon 1996, Venrock Portfolio, Articles N